UCLA have created the most extensive collection of patient-derived sarcoma organoids which are miniature versions of a ...

SAINT study is currently investigating intravenous trabectedin plus ipilimumab and nivolumab in the first line for advanced ...

Investigators developed the largest collection of sarcoma patient-derived organoids to date that can help improve the understanding of the disease and better identify therapies that are most likely to ...

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have developed the largest collection of sarcoma patient ...

Sarcomas are highly metastatic soft tissue and bone cancers and are often difficult to treat. Scientists have had trouble ...

There are around 100 different subtypes of sarcoma that can be classified into three broad groups: soft tissue sarcoma ... Here, the authors identify a crosstalk mechanism between tumor and ...

"Soft tissue sarcomas are a rare but heterogeneous mix of tumors with ... "would," or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, ...

Orphan Drug Designation in Soft Tissue Sarcomas Expands Company’s Potential to Address Cancers with High Unmet Medical Need CHICAGO and FORT WORTH, Texas, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Actuate ...

Fort Worth, Texas, clinical-stage biopharmaceutical company Actuate said elraglusib has shown a favorable safety profile and antitumor activity across several solid tumors, including melanoma, Ewing ...

This case demonstrates the pivotal role of a cohesive multidisciplinary team in navigating the complex care of oncology ...

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Thymic Carcinoma.

Patients with soft-tissue sarcoma treated with neoadjuvant, or pre-surgical, immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to ...